City of Providence, Rhode Island — commonly "Providence" — is the capital and largest city of Rhode Island, a municipal corporation headquartered at Providence City Hall, 25 Dorrance Street, Providence, RI. Settled in 1636 by Roger Williams and incorporated as a city in 1831, it operates under a mayor–council form of government with a Home Rule Charter (adopted 1980, effective 1983). Brett Smiley has served as mayor since January 2023; the City Council has 15 elected members. Population was 190,934 at the 2020 Census, making it the third-largest city in New England. It is a public entity, not a company: no ticker, no equity owners, funded by property taxes, state aid, and federal programs. Mayor Smiley's proposed FY2026 budget totals roughly $624 million; reported employee counts vary by source (commercial databases list figures in the high hundreds to low thousands), so no precise headcount is verified here.
Products / services / operations. Providence is a full-service municipal government. Its departments provide public safety (police and fire), sanitation and public works, water supply (Providence Water), planning and development, inspections and zoning, parks and recreation, libraries, workforce development, and general administration. The Providence Public School District is budgeted separately from the city's General Fund. The city is also a large purchaser of employee and retiree health benefits, operating a self-insured health and welfare benefit plan that reimburses prescription drug costs — the capacity in which it appears in the litigation below.
Patent-litigation posture. The tracked records show three plaintiff-side appearances, all filed June 18, 2020 in the Northern District of California, and zero defendant-side appearances. These are not patent infringement suits in which Providence asserts or defends patents. They are antitrust/end-payor actions challenging pharmaceutical "reverse payment" patent settlements, in which Providence participates as a purchaser of drugs, not as a patent holder or accused infringer. The "many plaintiff cases, zero defendant cases" pattern here reflects a repeat antitrust claimant, not a patent assertion entity.
Notable case context. All three tracked entries are City of Providence, Rhode Island v. Jazz Pharmaceuticals PLC (N.D. Cal., e.g. No. 3:20-cv-04064), concerning Xyrem (sodium oxybate). Providence alleged it overpaid for Xyrem because Jazz allegedly used patent settlements with generic ANDA filers to delay generic competition; it pleaded federal and Rhode Island antitrust and consumer-protection claims plus unjust enrichment. The suits were consolidated in December 2020 into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 20-md-02966 (N.D. Cal., Judge Richard Seeborg), alongside other named plaintiffs such as the A.G.C. Building Trades Welfare Plan and the New York State Teamsters Council Health and Hospital Fund. Jazz agreed in 2025 to pay $145 million and Hikma $50 million in settlements; Jazz and Hikma deny wrongdoing. Venue was MDL centralization, not a plaintiff-friendly patent forum such as the Eastern District of Texas.